Reblozyl Approved to Treat Anemia in ESA-Naive, Lower-Risk MDS
The approval was based on data from the phase 3 COMMANDS trial.
The approval was based on data from the phase 3 COMMANDS trial.
Ivosidenib produced an objective response rate of 83.3% in a phase 1 trial of patients with IDH1-mutated, relapsed or refractory MDS.
Survivors of common lymphoid neoplasms have an increased risk of therapy-related myelodysplastic syndrome/acute myeloid leukemia, data suggest.
Luspatercept appears more effective than epoetin alfa for treating anemia in patients with ESA-naïve, transfusion-dependent, lower-risk MDS.
Processed red meat intake is associated with an increased incidence of AML and MDS in a Japanese population, a study suggests.
Patients with abnormal chest CTs had worse overall survival, nonrelapse mortality, and pulmonary-related death after allo-HSCT.
A distinct mutational landscape and worse outcomes were seen for patients with MDS/AML vs those with MDS.
Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.
Blood supply shortages can delay transfusions by an average of 4 days for patients with myelodysplastic syndromes, a survey suggests.
About 40% of patients with lower-risk myelodysplastic syndromes die of the disease within 5 years, a study suggests.